United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Dai ichi Life Insurance Company Ltd

Dai ichi Life Insurance Company Ltd boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 10.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,202 shares of the biotechnology company’s stock after purchasing an additional 873 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in United Therapeutics were worth $2,931,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its holdings in shares of United Therapeutics by 176.2% during the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock worth $3,288,000 after purchasing an additional 9,133 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in United Therapeutics by 19.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after buying an additional 4,100 shares during the period. Comerica Bank lifted its stake in United Therapeutics by 5.9% in the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after buying an additional 9,244 shares during the last quarter. QRG Capital Management Inc. boosted its holdings in shares of United Therapeutics by 12.4% in the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after acquiring an additional 1,692 shares during the period. Finally, Campbell & CO Investment Adviser LLC grew its position in shares of United Therapeutics by 163.8% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 8,245 shares of the biotechnology company’s stock worth $1,813,000 after acquiring an additional 5,120 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $40,622.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $45,293.30. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $40,622.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 114,522 shares of company stock valued at $37,671,474. 12.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on UTHR shares. TD Cowen lifted their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. UBS Group upped their price objective on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. Oppenheimer lifted their target price on United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. Finally, Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $350.36.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $339.12 on Monday. The firm has a market capitalization of $15.09 billion, a price-to-earnings ratio of 16.03, a price-to-earnings-growth ratio of 1.23 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The business’s 50 day simple moving average is $336.73 and its 200-day simple moving average is $287.95. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period last year, the company posted $5.24 EPS. As a group, equities analysts forecast that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.